Yes, there are several cheaper options that work similarly to Januvia, and the landscape is shifting fast. Januvia (sitagliptin) currently costs around $350 for a 30-day supply without insurance, but you have alternatives ranging from other drugs in the same class to entirely different medication types that cost a fraction of the price. A generic version of Januvia was also approved by the FDA in late 2025, which should eventually bring the cost down significantly.
Generic Sitagliptin: FDA-Approved but Check Availability
The FDA approved the first generic version of sitagliptin (the active ingredient in Januvia) on December 30, 2025, manufactured by Watson Laboratories. This is the most direct substitute since it contains the identical medication at the same dose. However, FDA approval doesn’t guarantee the product is immediately on pharmacy shelves. Generic launches sometimes take weeks or months after approval, so it’s worth calling your pharmacy to ask whether generic sitagliptin is currently stocked and what the cash price is.
When generic sitagliptin becomes widely available, expect prices to drop substantially from the $350 brand-name cost. Generic medications typically cost 30% to 80% less than their brand-name counterparts, and prices tend to fall further as more manufacturers enter the market.
Other DPP-4 Inhibitors
Januvia belongs to a class of drugs called DPP-4 inhibitors, and there are several others in the same family. These all work the same way: they help your body produce more insulin after meals and reduce the amount of sugar your liver releases. The main alternatives include alogliptin (Nesina), linagliptin (Tradjenta), and saxagliptin (Onglyza).
A large meta-analysis of 98 clinical trials covering over 24,000 patients found that all DPP-4 inhibitors lower A1C by roughly the same amount, averaging about 0.77 percentage points. The Johns Hopkins Diabetes Guide puts the range at 0.5% to 1% A1C reduction across the class and notes that these drugs are “weight-neutral,” meaning they won’t cause the weight gain associated with some other diabetes medications. Because the blood sugar lowering effect is similar across all DPP-4 inhibitors, switching from one to another is generally straightforward. Your doctor can typically move you to a different one without a complicated transition.
One meaningful difference between these drugs involves kidney function. Linagliptin requires no dose adjustment regardless of how well your kidneys are working, which makes it the simplest option for people with kidney problems. The others all require lower doses as kidney function declines. On the cardiovascular safety front, sitagliptin and alogliptin have both been shown not to increase the risk of heart attacks, strokes, or heart failure hospitalizations. Saxagliptin, however, was linked to a higher rate of heart failure hospitalizations in one major trial, which is worth discussing with your doctor if that’s the alternative being considered.
Metformin: The Most Affordable Option
If cost is your primary concern, metformin is by far the cheapest diabetes medication available. It’s been generic for decades, and a 30-day supply typically costs under $10 at most pharmacies, sometimes as low as $4 through discount programs. Metformin is the first-line treatment for type 2 diabetes for good reason: it lowers blood sugar effectively, doesn’t cause weight gain (and may even help with modest weight loss), and has a long safety track record.
Many people take Januvia as an add-on to metformin rather than as a replacement for it. If you’re currently on Januvia alone and haven’t tried metformin, it’s worth asking your doctor whether metformin could be a suitable starting point. If you’re already on both, dropping Januvia and optimizing your metformin dose (along with lifestyle changes) could be an option depending on how well your blood sugar is controlled.
Combination Pills and Hidden Savings
If you take both metformin and a DPP-4 inhibitor, combination pills that bundle both into a single tablet exist. Janumet XR, which combines sitagliptin and metformin, costs about $330 for a 60-tablet supply without insurance. A generic version of the same combination (metformin/sitagliptin) runs around $246 for the same quantity, saving roughly $84 per fill. That’s not a dramatic discount, but it adds up over a year and simplifies your pill routine to a single tablet.
Merck’s Patient Assistance Program
If you’re uninsured and meet income requirements, Merck (the company that makes Januvia) offers a patient assistance program that can provide the medication at no cost. You may qualify if your household income falls below $63,840 for an individual, $86,560 for a couple, or $132,000 for a family of four. The program does not cover people who have any form of insurance, including Medicaid, Medicare, or private plans. Each enrollment lasts up to 12 months, covers up to a 90-day supply at a time with three refills, and requires a new application annually.
Medicare Enrollees: Price Drops Coming
If you’re on Medicare, Januvia’s cost is set to decrease notably. Through the federal government’s drug price negotiation program, the list price for Medicare enrollees is expected to drop to $113 for a 30-day supply in 2026. That’s roughly a 68% reduction from the current retail price. If you’re currently paying high copays on a Medicare Part D plan, this renegotiated price should lower your out-of-pocket costs as well. Januvia is typically placed on higher formulary tiers (Tier 3 or above), meaning higher copays, but the overall cost reduction should still flow through to what you pay at the pharmacy counter.
How to Talk to Your Doctor About Switching
The most practical path depends on why you’re taking Januvia in the first place. If it was prescribed because metformin alone wasn’t enough, ask whether a cheaper DPP-4 inhibitor like alogliptin or generic sitagliptin could replace it. If you’ve never tried metformin, that conversation is even simpler. Bring your pharmacy’s cash price for your current prescription and ask directly: “Is there a less expensive medication that would work just as well for me?”
Switching between DPP-4 inhibitors doesn’t require a gradual taper or transition period. If you’re also taking a sulfonylurea or insulin alongside your DPP-4 inhibitor, your doctor may want to adjust those doses when making any change, since the combination can increase the risk of low blood sugar. But the switch between drugs in this class is otherwise uncomplicated, and the blood sugar lowering effect you can expect will be very similar regardless of which one you end up on.